

ACRONYM: TERARMET



ADRESSED PATHOLOGY:

Fabry disease and Sanfilippo syndrome.

GENERAL OBJECTIVES:

Terarmet is focused on the **study and development of new therapies** for the treatment of the **Fabry disease** and the **Sanfilippo syndrome**. Both diseases are associated to a metabolic disorder, causing the storage of certain metabolites in the body.

The **main objectives** of the project are:

- 1) Development of new therapy tools based on **new delivery platforms**.
- 2) Development of **new tools for gene therapy** of the Sanfilippo syndrome

PARTICIPANTS:

- **Coordinator:** Praxis Pharmaceuticals.
- Praxis Biopharme Research Institute
- 3P Biopharmaceuticals
- Instituto de Materiales de Barcelona. ICMAB-CSIC. **Prof. Nora Ventosa**
- CIBER-BBN. **Dr. Simó Schwartz, Dr. Miriam Royo and Dr. J.L. Corchero**
- Fundación de Investigación Sanitaria de las Islas Baleares. FISIB. **Prof. Daniel Bachiller.**